<SEC-DOCUMENT>0001628280-24-036113.txt : 20240808
<SEC-HEADER>0001628280-24-036113.hdr.sgml : 20240808
<ACCEPTANCE-DATETIME>20240808160442
ACCESSION NUMBER:		0001628280-24-036113
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240808
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240808
DATE AS OF CHANGE:		20240808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38042
		FILM NUMBER:		241188117

	BUSINESS ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105
		BUSINESS PHONE:		626-696-4702

	MAIL ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARROWHEAD RESEARCH CORP
		DATE OF NAME CHANGE:	20040112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>arwr-20240808.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:f7111b88-bf41-4e2f-a330-b941708f3520,g:983d2533-0398-4628-be5b-561a5569f3dd,d:cf1e7e22d21640b9a502a2637cac0ac3-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>arwr-20240808</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0000879407</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-23">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="arwr-20240808.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-08</xbrli:startDate><xbrli:endDate>2024-08-08</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="icf1e7e22d21640b9a502a2637cac0ac3_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:115%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:115%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">WASHINGTON, D.C. 20549 </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:22.878%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:115%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:22.878%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">CURRENT REPORT </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">PURSUANT TO SECTION 13 OR 15(D) OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">THE SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August 8, 2024</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Date of Report </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(Date of earliest event reported)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:22.878%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Arrowhead Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Exact name of registrant as specified in its charter) </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:22.878%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:31.726%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.726%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.730%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38042</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">46-0408024</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(State or other jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">of incorporation)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(Commission</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">File Number)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">177 E. Colorado Blvd</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 700</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Pasadena</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-10">CA</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">91105</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Address of principal executive offices, including Zip Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">626</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">304-3400</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Registrant&#8217;s telephone number, including area code)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:22.878%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.345%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;text-indent:-24pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;text-indent:-24pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;text-indent:-24pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;text-indent:-24pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.054%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 2.38pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 2.78pt;text-align:center;text-indent:-0.8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 2.38pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">ARWR</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Emerging growth company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-21">&#9744;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9744;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="icf1e7e22d21640b9a502a2637cac0ac3_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 2.02 Results of Operations and Financial Condition </span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-24">August&#160;8, 2024</ix:nonNumeric>, Arrowhead Pharmaceuticals, Inc. announced and commented on its fiscal 2024 third quarter financial results for the period ended June 30, 2024. A copy of the press release is furnished herewith as Exhibit 99.1.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="icf1e7e22d21640b9a502a2637cac0ac3_10"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9.01. Financial Statements and Exhibits. </span></div><div style="margin-bottom:12pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d) Exhibits </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"/><td style="width:12.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="arwr-202408088kex991.htm">Press Release, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="arwr-202408088kex991.htm">August</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="arwr-202408088kex991.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="arwr-202408088kex991.htm">8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="arwr-202408088kex991.htm">, 2024.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="icf1e7e22d21640b9a502a2637cac0ac3_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURES </span></div><div style="margin-bottom:12pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </span></div><div style="margin-bottom:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-25">August&#160;8, 2024</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.969%"><tr><td style="width:1.0%"/><td style="width:23.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.129%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:73.369%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARROWHEAD PHARMACEUTICALS, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Kenneth Myszkowski</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Kenneth Myszkowski</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>arwr-202408088kex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i20233a22670144f48570c521dda57f02_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">EXHIBIT 99.1</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </font></div><div style="text-align:center"><img alt="ghvnqo5ppwcq000001a.jpg" src="ghvnqo5ppwcq000001a.jpg" style="height:67px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PRESS RELEASE</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">August 8, 2024</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results </font></div><div style="margin-top:6pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Conference Call and Webcast Today, August 8, 2024 at 4&#58;30 p.m. ET</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PASADENA, Calif., August 8, 2024</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Arrowhead Pharmaceuticals, Inc. (NASDAQ&#58; ARWR) today announced financial results for its fiscal 2024 third quarter ended June 30, 2024. The Company is hosting a conference call today, August 8, 2024, at 4&#58;30 p.m. ET to discuss the results.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Arrowhead had a very productive quarter with several high-profile presentations at medical and scientific congresses, as well as publications in high impact journals. Our clinical results have been strong and are receiving significant attention,&#8221; said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. &#8220;Across our diverse pipeline, we continue to make good progress in later-stage clinical studies and are approaching commercialization of both our wholly owned and partnered RNAi therapeutics. We also made critical progress on the financial front with two separate inflows that strengthen our balance sheet following our strategic decision to focus our resources in cardiometabolic on plozasiran, our most near-term commercial opportunity with a potential launch in 2025, provided plozasiran receives regulatory approval in familial chylomicronemia syndrome.&#8221;</font></div><div><font><br></font></div><div id="i20233a22670144f48570c521dda57f02_4"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:150%">Webcast and Conference Call and Details</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Investors may access a live audio webcast on the Company's website at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">https&#58;&#47;&#47;ir.arrowheadpharma.com&#47;events-and-presentations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. A replay of the webcast will be available approximately two hours after the conclusion of the call.<br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For analysts that wish to participate in the conference call, please register at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">https&#58;&#47;&#47;register.vevent.com&#47;register&#47;BI3ff87234939a4106b58ec6d3e72eb33c</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.</font></div><div id="i20233a22670144f48570c521dda57f02_7"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selected Recent Financial Events</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Strengthened the balance sheet to immediately enhance the ability of plozasiran to advance towards launch in 2025, if approved, and to expand the possibilities to fund innovation and growth across Arrowhead&#8217;s robust and diverse pipeline of RNAi therapeutics. Two key balance sheet events were&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">Closed a strategic financing agreement with Sixth Street for significant, long-term, non-dilutive capital. The $500 million senior secured credit facility includes $400 million funded at close with an additional $100 million available at Arrowhead&#8217;s option, subject to mutual agreement between Sixth Street and Arrowhead, during the seven-year term of the agreement.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Received a $50 million milestone payment from Royalty Pharma plc following the completion of enrollment of the Phase 3 OCEAN(a) - Outcomes Trial of olpasiran, being conducted by Amgen. Olpasiran, a small interfering RNA originally developed by Arrowhead using its proprietary Targeted RNAi Molecule (TRiM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) platform, is designed to lower levels of lipoprotein(a), a genetically determined risk factor for cardiovascular disease.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selected Recent R&#38;D Events</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Reported successful topline results from the pivotal Phase 3 PALISADE study of investigational plozasiran in patients with familial chylomicronemia syndrome (FCS). Plozasiran is the company&#8217;s first investigational RNAi-based therapy to show clinical efficacy in a Phase 3 study. Topline results included the following&#58;</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">Plozasiran achieved statistically significant median reductions in triglycerides up to 80% and mean reductions in APOC3 up to 94% at month 10.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">In addition to meeting the primary endpoint, plozasiran met all key secondary endpoints and demonstrated statistical significance versus placebo.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Plozasiran achieved a statistically significant reduction in incidence of acute pancreatitis versus placebo.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Plozasiran demonstrated a favorable safety profile in the PALISADE study. The number of subjects reporting treatment emergent adverse event (AEs) were similar in plozasiran and placebo groups. Severe and serious AEs were less common with plozasiran than with placebo. The most common AEs reported were abdominal pain, COVID-19, nasopharyngitis, headache and nausea.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Additional data from the PALISADE study of plozasiran will be presented in a late-breaking oral prestation at the European Society of Cardiology (ESC) Congress 2024 which is being held on September 2, 2024, in London. Details on the ESC presentation are listed below&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; A phase 3 study to evaluate the efficacy and safety of ARO-APOC3 in adults with </font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">familial chylomicronemia syndrome </font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#47;Time&#58; September 2, 2024, 11&#58;48 a.m. BST</font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presenter&#58; Professor Gerald Watts</font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Session&#58; Small trials, trial updates, and other studies on lipid therapy</font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Session Type&#58; Late Breaking Science</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Initiated pivotal Phase 3 SHASTA-3 and SHASTA-4 studies of plozaisran in patients with severe hypertriglyceridemia. </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announced plans to advance plozasiran into a Phase 3 cardiovascular outcomes trial called CAPITAN.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">CAPITAN builds upon existing SUMMIT program of pivotal Phase 3 clinical studies of plozasiran including PALISADE in patients with FCS and the SHASTA studies in patients with severe hypertriglyceridemia.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Presented new Phase 2 data from the MUIR study of investigational plozasiran in patients with mixed hyperlipidemia and the from the ARCHES-2 study of investigational zodasiran in patients with mixed hyperlipidemia at the European Atherosclerosis Society (EAS) 92</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Congress. Both studies were simultaneously published both studies in the New England Journal of Medicine.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Select MUIR results included the following&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">By silencing Apolipoprotein C-III (APOC3), plozasiran significantly reduced triglycerides and atherogenic triglyceride rich lipoproteins and increased HDL, across all dose levels at Week 24 in patients with mixed dyslipidemia.</font></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">At week 24, representing trough effect after two quarterly doses, plozasiran treatment was associated with placebo adjusted reductions in triglycerides of -50%, -56%, and -62% (all p&#60;0.001) at the 10, 25, and 50 mg doses, respectively. Fasting triglyceride levels were normalized (achieved levels below 150 mg&#47;dL) in most patients (79-92%) randomized to a treatment arm. Commensurate reductions in APOC3 of -57%, -73%, and -79%, with strong positive correlations with changes in triglyceride levels were observed.</font></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in other atherogenic lipoprotein parameters were also observed. At week 24, for the quarterly doses of 10, 25, and 50 mg, the following placebo adjusted changes were observed&#58; non-HDL-C levels -17%, -18%, and -24%&#59; apoB levels -10%, -13%, and -19%&#59; and remnant cholesterol levels -43%, -49%, and -48% with strong correlations with changes in triglyceride levels.</font></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Plozasiran demonstrated a favorable safety profile in the MUIR study. The overall rates of occurrence of treatment-emergent adverse events (TEAEs) and discontinuations were similar for plozasiran and placebo throughout the 48 weeks of observation. Observed adverse events generally reflected the comorbidities and underlying conditions of the study population. TEAEs occurring in five or more patients were COVID-19, worsening glycemic control, upper respiratory tract infection, urinary tract infection, headache, and bronchitis.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Select ARCHES-2 results included the following&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Zodasiran treatment was associated with dose-dependent placebo adjusted reductions in triglycerides, remnant cholesterol, LDL-C, ApoB, and Non-HDL-C across all dose levels in patients with mixed hyperlipidemia.</font></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">At week 24, representing trough effect, zodasiran treatment at 50, 100, and 200 mg on day 1 and week 12 was associated with placebo adjusted reductions in triglycerides of -51%, -57%, and -63% (all p&#60;0.001) respectively. ANPTL3, the genetic target of zodasiran, was reduced compared with placebo by -54%, -70%, and -74%, and remnant cholesterol levels were reduced by -73%, -76%, and -82%, which strongly correlated with changes in triglyceride levels.</font></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in other atherogenic lipoprotein parameters were also observed across all three dose levels. At week 24, the following placebo adjusted changes were observed for the 200 mg dose&#58; LDL-C -20%, ApoB -22%&#59; Non-HDL-C -36%.</font></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In a subset of patients with baseline liver fat fraction greater than 8%, dose-dependent liver fat reductions, measured by MRI-PDFF, were observed reaching -28% with the 200 mg dose compared with -2% with placebo.</font></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Zodasiran demonstrated a favorable safety profile in patients with mixed hyperlipidemia in the ARCHES-2 study. Treatment-emergent adverse events (TEAEs) were generally balanced between treatment and placebo groups and generally reflected the comorbidities and underlying conditions of the study population. There were no clinically meaningful changes in laboratory safety evaluations, no changes in mean platelet counts, and modest changes in HbA1c.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Presented final data from the Phase 2 SHASTA-2 study of investigational plozasiran in patients with severe hypertriglyceridemia in a late-breaking oral presentation at the American College of Cardiology 73</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Annual Scientific Session &#38; Expo and simultaneously published in the journal JAMA Cardiology. Key results included the following&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Treatment with plozasiran led to dose-dependent placebo-adjusted reductions in triglycerides (primary endpoint) of -49% (P &#60; 0.001), -53% (P &#60; 0.001), and -57% (P &#60; 0.001), driven by placebo-adjusted reductions in APOC3 of -68% (P &#60; 0.001), -72% (P &#60; 0.001), and -77% (P &#60; 0.001) at week 24, after receiving two doses of 10 mg, 25 mg, and 50 mg plozasiran, respectively. Mean maximum, non-placebo adjusted reductions from baseline in triglycerides and APOC3 were up to 86% and 90% and typically occurred around week 16 or week 20.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Among patients treated with plozasiran, 90.6% achieved a triglyceride level less than 500 mg&#47;dL, the level associated with increased risk of acute pancreatitis, at week 24. In addition, 48.4% of patients achieved normal triglyceride levels of less than 150 mg&#47;dL at week 24.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Subjects treated with plozasiran also showed improvements in multiple atherogenic lipid and lipoprotein levels, including remnant cholesterol, HDL-cholesterol, and non-HDL cholesterol.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Plozasiran demonstrated a favorable safety profile in the SHASTA-2 study. The adverse event and serious adverse event profile were similar across treatment groups. Observed adverse events generally reflected the comorbidities and underlying conditions of the study population.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Presented preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, at the American Diabetes Association (ADA) 84</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Scientific Sessions. In pharmacological studies in obese and diabetic mouse models, INHBE siRNA administration resulted in multiple promising findings, including the following&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">95% reduction in INHBE mRNA expression</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">19% suppression of body weight compared to saline controls</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">26% loss of fat mass</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Preservation of lean mass</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Presented new interim clinical data on ARO-RAGE, an investigational RNAi-based medicine for the treatment of inflammatory lung diseases, such as asthma, at the American Thoracic Society (ATS) 2024 International Conference. Key results included the following&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Single and multiple doses of ARO-RAGE in normal healthy volunteers led to dose dependent reductions in soluble RAGE (sRAGE) in both bronchoalveolar lavage fluid (BALF) and in serum.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">After two doses of ARO-RAGE in patients with mild to moderate asthma, serum sRAGE was reduced up to 88% with a mean maximum reduction up to 77%.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Serum sRAGE was reduced in a dose-responsive manner with similar reductions observed in NHVs and patients with asthma at each dose level.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Pharmacodynamic effects were long lasting, with a duration that appears to support once every two-month dosing.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">ARO-RAGE has shown a favorable safety profile to date, with no demonstrated pattern of effect on systemic safety labs and no demonstrated pattern of detrimental effect on lung function (FEV1, FVC, or DLCO) over time. There have been no serious adverse effects related to study drug and no treatment emergent adverse events leading to trial withdrawal or study drug discontinuation.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Arrowhead also presented preclinical data at ATS on two additional lung targeted programs&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">ARO-TSLP is designed to silence the epithelial cytokine thymic stromal lymphopoietin (TSLP), a genetically and clinically validated therapeutic target that activates multiple immune cell lineages to promote asthmatic inflammation.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">ARO-IAV is designed to silence expression of highly conserved influenza A viruses, including the highly pathogenic avian influenza virus (H5N1).</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Launched the 2024 Summer Series of R&#38;D webinars to highlight specific therapeutic areas in Arrowhead&#8217;s pipeline. Each event will feature presentations by Arrowhead team members and external key opinion leaders, who will discuss the respective disease areas and treatment landscapes. 2024 Summer Series Schedule&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">May 23, 2024 &#8211; Muscular</font></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Completed</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">June 25, 2024 &#8211; Cardiometabolic</font></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Completed</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">July 16, 2024 &#8211; Pulmonary</font></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Completed</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">August 14, 2024 &#8211; Obesity&#47;Metabolic</font></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">New date planned</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">September 25, 2024 &#8211; Central Nervous System</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i20233a22670144f48570c521dda57f02_10"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Selected Fiscal 2024 Financial Results</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ARROWHEAD PHARMACEUTICALS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">CONSOLIDATED CONDENSED FINANCIAL INFORMATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(in thousands, except per share amounts)</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:70.068%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Three Months Ended June 30,</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%;text-decoration:underline">OPERATING SUMMARY</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Revenue</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15,825</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Operating Expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.72pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,431&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,757&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.72pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">General and administrative expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,710&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,771&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total Operating Expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">176,141&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">118,528&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating loss</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(176,141)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102,703)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.72pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total other income (expense)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,164&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(680)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Loss before income tax expense and noncontrolling interest</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(173,977)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(103,383)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.72pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Income tax expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net loss including noncontrolling interest</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(173,977)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(104,125)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net loss attributable to noncontrolling interest, net of tax</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,184)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,179)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(170,793)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(102,946)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net loss per share attributable to Arrowhead Pharmaceuticals, Inc. - Diluted</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1.38)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.96)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Weighted-average shares used in calculating - Diluted</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,199&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,004&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%;text-decoration:underline">FINANCIAL POSITION SUMMARY</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br>2024</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30,<br>2023</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash, cash equivalents and restricted cash</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,399&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,891&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">367,272&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">292,735&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total cash resources</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">436,671</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">403,626</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">447,088&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">361,926&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total Assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">883,759</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">765,552</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Current deferred revenue</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">544,785&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">477,524&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total Liabilities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">544,785</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">478,390</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total Arrowhead Pharmaceuticals, Inc. Stockholders' Equity</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">330,547</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">271,343</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Noncontrolling Interest</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">8,427</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15,819</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total Noncontrolling Interest and Stockholders' Equity</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">338,974</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">287,162</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total Liabilities, Noncontrolling Interest and Stockholders' Equity</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">883,759</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">765,552</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Shares Outstanding</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,227&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">107,312&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                                                  </font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </font></div><div id="i20233a22670144f48570c521dda57f02_13"></div><div><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">About Arrowhead Pharmaceuticals</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead&#8217;s RNAi-based therapeutics leverage this natural pathway of gene silencing.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at &#64;ArrowheadPharma or on </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">LinkedIn</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. To be added to the Company's email list and receive news directly, please visit </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">http&#58;&#47;&#47;ir.arrowheadpharma.com&#47;email-alerts</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Safe Harbor Statement under the Private Securities Litigation Reform Act&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">This news release contains forward-looking statements within the meaning of the &#34;safe harbor&#34; provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;hope,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;target,&#8221; &#8220;forecast&#8221; or &#8220;continue&#8221; or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs&#59; our expectations regarding the potential benefits of the partnership, licensing and&#47;or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future&#59; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements&#59; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Contacts&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Arrowhead Pharmaceuticals, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vince Anzalone, CFA</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">626-304-3400</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">ir&#64;arrowheadpharma.com</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Investors&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LifeSci Advisors, LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Brian Ritchie</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">212-915-2578</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">britchie&#64;lifesciadvisors.com</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Media&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LifeSci Communications, LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Kendy Guarinoni, Ph.D.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">724-910-9389</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">kg</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">uarinoni&#64;lifescicomms.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Source&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Arrowhead Pharmaceuticals, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%"># # #</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>arwr-20240808.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:f7111b88-bf41-4e2f-a330-b941708f3520,g:983d2533-0398-4628-be5b-561a5569f3dd-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:arwr="http://www.arrowheadresearch.com/20240808" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arrowheadresearch.com/20240808">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20240808_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20240808_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.arrowheadresearch.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>arwr-20240808_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:f7111b88-bf41-4e2f-a330-b941708f3520,g:983d2533-0398-4628-be5b-561a5569f3dd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_2b2bdee9-a4c7-474d-9dbf-4be73f2ee38c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_32426d0a-6332-4991-a511-70ac240e601a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_d1b30472-2478-4dc2-8b1e-26a283e7693e_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_2316b701-0528-4b26-9e27-192de7556539_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f4430188-1acd-48ba-a599-8e7acd3d677d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7a8672ed-fdd3-4d29-bd6e-12a755b1d78d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_cd6b8c07-3b15-4018-a4ac-c9836153ba71_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_7e47833b-c4f7-42b2-9cb8-feb9765750e0_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_d83247c8-b87d-44e0-8c21-9bae5f882450_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_5dd4257d-263b-4921-8494-8b4e67ff0cea_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_a6f7c9e6-7a74-419d-a1a0-190d5d46b3b2_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_890c536a-1836-4b7b-9ba7-90ca49c20d77_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1e20f236-d5fb-459e-b0c2-3ba93923d4fe_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8e20dbbf-5099-47da-a568-36c52900c90c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_359c3647-d007-497c-b39f-64c8a4bb6cad_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_6c50d632-6b05-4db7-8ef4-ac053e500699_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_325b5d24-3219-478c-a695-84e69a21c062_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_eb0c2cff-f2b2-484a-97e8-d565be6fb796_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_716bf2fd-3f9a-4637-841d-8696996973c4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_83338f86-767c-420f-9cad-1d29d21eebbf_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_38db2535-88d4-4beb-b752-7bdf32d661da_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_febdeda7-e680-46e9-a6a4-2817a68e9508_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a26d7047-716e-4d17-b065-2991e2638037_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>arwr-20240808_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:f7111b88-bf41-4e2f-a330-b941708f3520,g:983d2533-0398-4628-be5b-561a5569f3dd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/Cover" xlink:type="simple" xlink:href="arwr-20240808.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_0fd923b7-371b-41f0-91f5-5d4140e31b53" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_03c6909b-1ecb-497d-ae33-b9916ef6592e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0fd923b7-371b-41f0-91f5-5d4140e31b53" xlink:to="loc_dei_DocumentType_03c6909b-1ecb-497d-ae33-b9916ef6592e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c6161064-78b3-4fd3-9195-8e1adaac14a3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0fd923b7-371b-41f0-91f5-5d4140e31b53" xlink:to="loc_dei_DocumentPeriodEndDate_c6161064-78b3-4fd3-9195-8e1adaac14a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_223dac25-83e1-4b7e-beec-8418524f985c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0fd923b7-371b-41f0-91f5-5d4140e31b53" xlink:to="loc_dei_EntityRegistrantName_223dac25-83e1-4b7e-beec-8418524f985c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7eed3c96-9859-4093-9156-5af0f9a02d18" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0fd923b7-371b-41f0-91f5-5d4140e31b53" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7eed3c96-9859-4093-9156-5af0f9a02d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_66a1cd94-c630-405f-9b3b-d1d539f2853c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0fd923b7-371b-41f0-91f5-5d4140e31b53" xlink:to="loc_dei_EntityFileNumber_66a1cd94-c630-405f-9b3b-d1d539f2853c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_171ef953-d577-4588-a899-41798f873a19" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0fd923b7-371b-41f0-91f5-5d4140e31b53" xlink:to="loc_dei_EntityTaxIdentificationNumber_171ef953-d577-4588-a899-41798f873a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_da912ccc-cd13-45ed-99f8-cc979d4d32d6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0fd923b7-371b-41f0-91f5-5d4140e31b53" xlink:to="loc_dei_EntityAddressAddressLine1_da912ccc-cd13-45ed-99f8-cc979d4d32d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_9621ecd3-d1aa-46cb-9b0f-1caba86e34ef" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0fd923b7-371b-41f0-91f5-5d4140e31b53" xlink:to="loc_dei_EntityAddressAddressLine2_9621ecd3-d1aa-46cb-9b0f-1caba86e34ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7667b3f4-989a-48e9-83e2-78a9863dd14c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0fd923b7-371b-41f0-91f5-5d4140e31b53" xlink:to="loc_dei_EntityAddressCityOrTown_7667b3f4-989a-48e9-83e2-78a9863dd14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_43de4364-f96b-49ea-ad57-f934b1d49733" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0fd923b7-371b-41f0-91f5-5d4140e31b53" xlink:to="loc_dei_EntityAddressStateOrProvince_43de4364-f96b-49ea-ad57-f934b1d49733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b2511c3d-79e1-4706-847e-5d26daa9abfe" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0fd923b7-371b-41f0-91f5-5d4140e31b53" xlink:to="loc_dei_EntityAddressPostalZipCode_b2511c3d-79e1-4706-847e-5d26daa9abfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7130ff37-490e-47aa-88a7-82d6aa086f8d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0fd923b7-371b-41f0-91f5-5d4140e31b53" xlink:to="loc_dei_CityAreaCode_7130ff37-490e-47aa-88a7-82d6aa086f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c58a4d7c-a89e-4214-9d7c-9a4a67804806" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0fd923b7-371b-41f0-91f5-5d4140e31b53" xlink:to="loc_dei_LocalPhoneNumber_c58a4d7c-a89e-4214-9d7c-9a4a67804806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_f1f9b58a-ba40-44b8-ad28-77c48887d6d4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0fd923b7-371b-41f0-91f5-5d4140e31b53" xlink:to="loc_dei_WrittenCommunications_f1f9b58a-ba40-44b8-ad28-77c48887d6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_e8db84d6-eb56-4d92-8a38-d931e9e32f7c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0fd923b7-371b-41f0-91f5-5d4140e31b53" xlink:to="loc_dei_SolicitingMaterial_e8db84d6-eb56-4d92-8a38-d931e9e32f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_0e46d72f-c945-4711-9074-488f224083ef" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0fd923b7-371b-41f0-91f5-5d4140e31b53" xlink:to="loc_dei_PreCommencementTenderOffer_0e46d72f-c945-4711-9074-488f224083ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_2bffd439-d3a3-4dcd-904c-bd0eead825d8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0fd923b7-371b-41f0-91f5-5d4140e31b53" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_2bffd439-d3a3-4dcd-904c-bd0eead825d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d01f866b-3855-465c-975a-16e72ef5a936" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0fd923b7-371b-41f0-91f5-5d4140e31b53" xlink:to="loc_dei_Security12bTitle_d01f866b-3855-465c-975a-16e72ef5a936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a24297ff-819f-487e-a111-7ca2f130a03c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0fd923b7-371b-41f0-91f5-5d4140e31b53" xlink:to="loc_dei_TradingSymbol_a24297ff-819f-487e-a111-7ca2f130a03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_5203fa32-d7ea-4370-8b37-5b00e9f370f7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0fd923b7-371b-41f0-91f5-5d4140e31b53" xlink:to="loc_dei_SecurityExchangeName_5203fa32-d7ea-4370-8b37-5b00e9f370f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0acbec93-e38d-4411-9f5f-e224d9e00bdf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0fd923b7-371b-41f0-91f5-5d4140e31b53" xlink:to="loc_dei_EntityEmergingGrowthCompany_0acbec93-e38d-4411-9f5f-e224d9e00bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_82cdb272-1f6f-41ac-b609-2c6ed4d2b3c8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0fd923b7-371b-41f0-91f5-5d4140e31b53" xlink:to="loc_dei_EntityCentralIndexKey_82cdb272-1f6f-41ac-b609-2c6ed4d2b3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b4a92c5b-c4b7-48b9-a942-caf7a11bb8bc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0fd923b7-371b-41f0-91f5-5d4140e31b53" xlink:to="loc_dei_AmendmentFlag_b4a92c5b-c4b7-48b9-a942-caf7a11bb8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ghvnqo5ppwcq000001a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ghvnqo5ppwcq000001a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )8!P@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HK*U/Q'I6D9%W>(L@_Y9)\S_D.GXUQVH_$QSE--L0H
M[27!R?\ OD?XUO2PU6I\*,IUZ<-V>C55NM2L;+_CZO((/:20*?UKQJ^\4ZWJ
M&1/J$P4_P1'8OY+C/XUD$DDDG)/4FNZ&6/[<CEECE]E'L=QXY\/P9 O3*1VC
MC8_KC%9TOQ+TE>(K6\<^I55'\Z\LHKHCEU%;W9B\94>QZ2WQ/M@?DTR4CWE
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!X+/_Q\2?[Y_G4=23_\?$G^^?YU'69H>S>%
MO^17T_\ ZY#^=;%8_A;_ )%?3_\ KD/YUL5H9A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 4]6_Y U]_P!>\G_H)KPVO<M6_P"0-??]>\G_ *":\-J9%1"O
M=K'_ )!]M_UR7^0KPFO=K'_D'VW_ %R7^0HB$BQ1115$A1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /!9_
M^/B3_?/\ZCJ2?_CXD_WS_.HZS-#V;PM_R*^G_P#7(?SK8K'\+?\ (KZ?_P!<
MA_.MBM#,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO7&W\E'^->85ZW\.XO+\+!L?ZR=V_D/Z5PY@[4?F=6#5ZIUE%%%>">L%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >"S_\
M?$G^^?YU'4D__'Q)_OG^=1UF:'LWA;_D5]/_ .N0_G6Q6/X6_P"17T__ *Y#
M^=;%:&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8="IP170Z7XUU?3F59)OM<(ZI-R?P;K_ #HN'*>MT5C:'XEL-=CQ"QCN ,M
M_P!X>X]16S5$A1110 4444 %%%% !144]Q#:PM-/*D42C+.YP!7%ZM\1((BT
M6EP><P_Y;2@A?P'4_I1<+'<U7GOK2U_X^+J"'_KI(%_G7C]]XFUC4"?/OI0I
M_@C.Q?R'7\:R223D\DU/,5RGM9\1:,"0=4M./24&E3Q!H\C875+//O,H_K7B
M=%','*>]13Q3KNAE21?5&!'Z5)7@D<LD+AXI&1QT93@UO:=XTUJP(#7'VF,?
MP3C=_P"/=?UHN'*>NT5S6B^-=-U5EAF/V2X/ 21OE8^S?XXKI:HD**** "BB
MB@ HHHH ***J:AJ=GI=OY][<)$G;)Y;V ZF@"W17G>J?$65RT>EVPC7_ )ZS
M<M^"]!^.:Y2]UK4]1)^UWLT@/\);"_D.*5QV/9)M3L+8XGOK:(^CRJO\S5;_
M (2/1?\ H*6O_?T5XK12YA\I[?%KFDS'$>I6C'T\Y<_EFKRLKJ&1@RGH0<@U
MX%4]M>75F^^UN)86]8W*_P J.8.4]WHKRW3?'^J6C!;P)=Q=\C:X_$?U%=YH
M_B/3M;3%M+MF ^:&3AQ_B/I3N)HUJ**\O\6ZUJ=IXGO(+>_N(HEV;420@#**
M:&P2N>H45XK_ ,)'K7_04N_^_IKN_ -_=W]C>/=W,L[+( ID;.!BA,&CKZ**
M*8@HHHH ***P=9\6Z9HQ,;2&>X'_ "RB()'U/0?SH WJ:[I&I9V55'4L<"O*
M]1\=ZO>DK;LMI$>T8RWXL?Z8KG+BZN+I]]Q/+,_]Z1RQ_6E<KE/:9==TF$XD
MU.T!]/.7/\ZC_P"$CT7_ *"EI_W]%>*T4N8.4]T@U&QN3BWO;>4GH(Y5;^1J
MU7@-:5EK^JZ<1]FOIE4?P,VY?R/%','*>V45P.D_$4$K'JMN%[>="/YK_A^5
M=Q:W=O?6ZSVLR2Q-T93D55Q6(=6_Y U]_P!>\G_H)KPVO<M6_P"0-??]>\G_
M *":\-J9#B%>[6/_ "#[;_KDO\A7A->[6/\ R#[;_KDO\A1$)%BBBBJ)"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\_\
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MHHHJB3 \;?\ (H7W_;/_ -&+7D%>O^-O^10OO^V?_HQ:\@J64BYI/_(9L?\
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M[5T.UNB<N4VR?[PX/^/XUIU9 4444 %%%% !7DOC?4OM_B*2-6S%:CRE^O\
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M)&.5'^TO;]17/4AGIOA/QA_:16PU!@MWC$<O02^W^]_.N1\;?\C???\ ;/\
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MJ("BBB@ HHHH *X;Q7X+29'O]*BVS#F2!1P_NH]?;O\ S[FB@$SP&BNS\>:
MME=#4[9,0SMB50.%?U_'^?UKC*@L*]'^&W_(/OO^NJ_RKSBO1_AM_P @^^_Z
MZK_*A;@]CMZ***L@YOQIK9TG1_*A;%S=91".JC^(_KC\:\EK?\8ZD=1\1W&&
MS% ?)3GCCJ?SS6!4,M+0*]#\(^#D1(]1U2(,[ -# PX4>K#U]O\ (Q?!&A#5
M-3-U<)FUM2#@]'?L/Z_EZUZK32$V%%%%42%%%% !1110!7O;&VU&U:VNX5EB
M;J&[>X]#7E'B;PS-H-SO3=)92']W)W'^RWO_ #KU^JU]90:C92VERFZ*5<'U
M'N/<4FAIV/"J*N:KITNDZG/93?>C;AO[P['\15.I+"O=K'_D'VW_ %R7^0KP
MFO=K'_D'VW_7)?Y"G$F18HHHJB0HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /)/B'<^?XH:+/%O"B?B?F_]FKDZU?$L_P!I
M\3:E)G/^D,H/LIP/Y5E5]-0CRTHKR/#JRYIMA1116QF%%%% !1110 4444 %
M>D_#?1A';3:O*OS2YBASV4'YC^)X_ UYS%$\\T<,8W.[!5'J3P*][T^RCT[3
MK>SB^Y#&$!]<=3^->=F-7EI\BZG9@Z?-/F?0LT445XAZ@4A( R> *6N'\=^(
M6@3^R+5\.ZYG8'HI_A_'O[?6HJ34(W9G5J*G'F95\3^-G=WLM)DVH/E>Y7JW
MLOH/?\JX8DLQ9B2Q.23WI**\N=24W=GB5:LJCO(****@S"BBB@"Q97USIURM
MQ:3/%*O=3U]CZBO4?#/BJ'7(_(F"Q7RC)0'AQZK_ (5Y-4D$\MK/'/"Y26-M
MRL.H-;4JKIOR-Z%>5)^1[Q163X=UJ/7-*2X&!,OR3(.S?X'K6M7IQ:DKH]J,
ME)<R"BBBF4>+^,-'&C:_+'&N+>;][%CH >H_ Y_#%8%>K?$731=:"MXJ_O+1
M\D_[+<']<?E7G.AV7]H:Y96A&5DF4,/]G.3^@-?0X6OST.:73?Y'CUZ7+5Y5
MU/9]"M/L&@V-L1ADA7</]K&3^N:@\47GV'PSJ$^<-Y113[M\H_G6O7#_ !+O
M?*TFULP<&>4N?HH_Q8?E7C4(NK75^K/2JODI/T/,****^D/%"BBB@ HHHH *
M*** "BBE +$ #)/ % 'L'@.U^S>%+=B,-.[2G\\#] *Z:JNG6HLM,M;4?\L8
MEC_( 5:KY>K/GFY=V>[3CRP2"BBBLRPHHHH **** "BBB@ HHHH *CGE6""2
M9_NQJ6/T S4E9/B:7R?#.HN#C,#+^?']: /&YYGN+B2>0Y>1B['W)R:CHI54
MLZJ.I.!69H>M^"M/%AX;@<C$ES^^8^QZ?IC\ZZ*HX(E@MXX4^[&H4?0#%25H
M9A1110 4444 %%%% !1110!QGQ$TT3Z5#?J/GMWVL?\ 9;_Z^/S->:5[;K]N
M+KP_?PXR3 Y'U R/U%>)5+*05[=H7_(O:;_UZ1?^@"O$:]NT+_D7M-_Z](O_
M $ 41"1H44451)@>-O\ D4+[_MG_ .C%KR"O7_&W_(H7W_;/_P!&+7D%2RD%
M>D_#FP$6F7-\P^:>38O^ZO\ ]<G\J\VKVCPS;?9/#6GQ8QF$.?JWS'^="![&
MM1115$A1110 4444 %>6?$+_ )&1?^O=?YM7J=>6?$+_ )&1?^O=?YM28X[G
M*4Z*-II4B09=V"J/4FFUM>$K;[7XHL4(^5'\P_\  02/U J2CUVRM4LK&"UC
M^Y#&$'X"IZ**L@**** "BBB@#S_XDWAW6-D#QAIF'Z#_ -FK@:ZCQ]*9/$[J
M<_NX44?S_K7+U#+6QT/@O31J'B.$NN8[<><P]QT_4C\J]=K@_AK;@07]R1RS
M+&#] 2?YBN\JEL2]PHHHIB"BBB@ HHHH **** "O*/'6G"Q\0M,@Q'=+YO\
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M_P"%EP_] Q_^_P /\*+H+,[NBN$_X67#_P! Q_\ O\/\*/\ A9</_0,?_O\
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M0?;?]<E_D*\)KW:Q_P"0?;?]<E_D*(A(L44451(4444 %%%% !1110 4444
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M_-(SM]2<UT9;3O-S[&.-G:*CW(:***]H\P**** "BBB@ HHHH *U_#%G]O\
M$NGP8ROFAV'LOS'^59%=Q\-++S=5NKPCY8(@@/\ M,?\ ?SK#$3Y*4I&M&/-
M42/3ZYCQ=J+6DNCVT;8:>^C8CU56!Q^96NGKS/QEJ D\<:? #E;1HLC_ &BP
M8_IMKP\)3YZOI<]3$3Y8'IE%%%<QN%%%% !1110 4444 %%%% !6'XP_Y%2_
M_P!Q?_0A6Y61XHB\[PQJ*@9Q"6_[YY_I0"/&*L6/_(0MO^NJ_P Q5>G(YCD5
MUZJ014&A[Y13(I5FACE0Y5U#+]#3ZLS"BBB@ HHHH **** "BBB@"&[V_8I]
MYPOEMGZ8KP>O;]:G%MH=_,3C;;N1]<''ZUXA4R*B%>W:%_R+VF_]>D7_ * *
M\1KV[0O^1>TW_KTB_P#0!1$)&A1115$F!XV_Y%"^_P"V?_HQ:\@KU_QM_P B
MA??]L_\ T8M>05+*0JJ68*.I.!7O448BB2-?NHH4?A7ANFIYFJ6B'^*9!_X\
M*]UHB$@HHHJB0HHHH **** "O+/B%_R,B_\ 7NO\VKU.O+/B%_R,B_\ 7NO\
MVI,<=SE*Z[X=Q!_$$LA_Y9V[$?4E1_C7(UW/PU7-YJ#>D:#\R?\ "I6Y3V/1
M:***L@**** "BBB@#R#QM_R-]]_VS_\ 1:U@5T_CV(Q^*)&/_+2)&'Y8_I7,
M5#+6QZ=\.,?V!<=-WVIL_P#?*UV%<+\-9P;6_M\\JZN/Q!']*[JJ6Q+W"BBB
MF(**** "BBB@ HHHH *Y/XA?\BVO_7PO\FKK*XKXD3A=*L[?/,DY?_OE2/\
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M_P#?D_XT6871PE%=W_PK2;_H)Q_]^3_C1_PK2;_H)Q_]^3_C19A='"45W?\
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M_P A7A->[6/_ "#[;_KDO\A1$)%BBBBJ)"BBB@ HHHH **** "BBB@ HHHH
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M5_M+Q%)&C9AM1Y*_4?>/Y\?A7,U]#@J7LZ*ON]3Q\34YZC\@HHHKK.<****
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M1>TW_KTB_P#0!3B*1H44451)@>-O^10OO^V?_HQ:\@KU_P ;?\BA??\ ;/\
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MQ_Y!]M_UR7^0IQ%(L44451(4444 %%%% !1110 4444 %%%% !1110 4444
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M.IS'$?)3Z+P?US6#7KX2G[.BD>=B)\]1L^AZ*CM_^/:+_<'\JDKYP]H****
M"BBB@ HHHH **** "BBB@#F_&>BG5M&,D*YN;;,B =6'\0_K^%>2U[]7E_C3
MPT=.N6U"TC_T.5LNJC_5,?Z'_P"MZ5+129R->C>#O%J3QQZ9J,@691MAE8\.
M.RGW_G]>OG-%),;1[]17E^@^.KK3U6WOU:ZMQP'S^\4?U_'\Z[W3O$&EZJH^
MRWD9<_\ +-CM?\C_ $JDR6C3HHHIB"BCIS6-J7BG2-,4^;=I)(/^64)WM^G
M_'% &S7G_C/Q:DD<FEZ=)N!^6>93P1_=']3^%9.O>-;W5E>WMP;6U;@A3\[C
MW/\ 0?K7+U+92045:T^PGU.]2UMUR[<D]E ZD^U5:105[=H7_(O:;_UZ1?\
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MW!Q_?;=_.LBB@9KR>*=<ESNU.<9_NG;_ "K-GNKBZ??<3RS-_>D<L?UJ*B@
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MR0R##*W>IJ* /)O$OA&XT61KBW#36)/#]3'[-_C7-5[Z0&!! (/!![UR&M>
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MMO\ KDO\A7A->[6/_(/MO^N2_P A1$)%BBBBJ)"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH S/$.G_VIX?O;0#+O&2@_P!H
M<C]0*\+KZ'KQ3Q;IG]E>([J(+B*1O.C_ -UN?T.1^%>KEE35TWZG!CH;3,.B
MBBO7/."BBB@ HHHH **** "BBB@#IO!_B=M"O##<$FPF/S@<[&_O#^O_ -:O
M7TD26-9(V#HPRK*<@CU%?/5=9X3\8RZ*RV=YNEL&/&.6B/J/;U'Y>_FXW!^T
M]^&_YG;AL3R>Y+8];HJ&VNH+RW2XMI5EA<95U.0:FKQ6K:,],**** "BBB@
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M"BBB@ HHHH **** "BBB@ HHHH **** "J%WHFEWQ)N;""1CU;8 WYCFK]%
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M5)THHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *XOXBZ3]KTF/4(US):G#X'5#_ (''YFNTJ.>&.Y@D@E7='(I1
ME]01@UK1J.G-370BI!3@XL^?**T-:TN71M6N+&7GRV^1O[RGH?RK/KZ6,E)7
M1X;33LPHHHJA!1110 4444 %%%% !1110!K:)XBU#09]]K)F)CEX7Y1O\#[B
MO3M$\::7K 6-I!:W1_Y92MP3_LMT/Z'VKQNBN6OA*=;5Z/N;TL1.GHMCZ'HK
MQ+2_%>L:2%2"[9X1_P LIOG7Z#N/P(KK++XG(0!?Z>P/=X'S_P".G_&O+J9?
M5C\.IWPQE.6^AZ#17,P>/?#\P^:Z>$GM)$W] 15P>+= (!&J0<^N1_2N9T*J
MWB_N-E5IO9HVJ*PW\8>'XQEM3B/^Z&;^0K.NOB)H< /D_:+@]MD>!_X]BG'#
MU9;18.M36\D=;3)98X(FDFD2.-1EF=L ?C7FM_\ $N]E!6PLXH!_?D.]ORX
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M@TD^$M/).?D/_H1K=KY>M_$EZL]VG\"] HHHK,L**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M("OC/!QVKQ"O6_ O_(J6W^^__H1J4RFCHZ***HD**** "BBB@ HHHH ****
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M*M"_7J>/7HNE*W0;111728!1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWD&Z%SU(]#[C_"IO!NI-IWB*W&[$5P?)<?7H?SQ^M"T&]3U^N0^(W_(O6_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KFO$_A"VUY#/"5@O@.),</[-_C72T
M5=.I*G+FB]29PC-6D> WUA=:;=O:WD+12KU#=_<'N/>JU>[:QHECK=KY%Y%N
MQ]R1>&0^H->5>(/"-_H3M)M-Q9YXG0=/]X=OY5[F&QL*NDM&>76PTJ>JU1SU
M%%%=IRA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6IHF@
MWNNW?DVJ80']Y*WW4'O[^U;OASP'=ZD5N=1#VMIU"D8DD_#L/<UZ=9V5MI]J
MEM:0K%"G15'^<FO/Q..C3]V&K.RAA7/66B*6AZ!9Z!9^3:KF1O\ 62M]YS_A
M[5JTUW6-&=V"HHR68X %>;^*O'9N!)8:0Y6(_+)<C@M[+Z#WKRZ=*IB)_FSN
MG.%&)?\ &/C1;42:;I<N;CE9IE_Y9^P_VO?M]>GFA))R3DFDHKW:%"-&/+$\
MJK5E4E=A1116YD%%%% !1110 4444 7=)U.?1]3AO;<_/&>5/1AW!^M>U:1K
M%IK5BMU:2!AT=/XD/H:\(JYIVIWFDW0N;*=HI!P<=&'H1W%<>*PBKJZT9TX?
M$.D[/8][HKB-&^(UG<A8M4C^S2]/-0%D/]1^M=E;W,%W")K>:.:-NCQL&!_$
M5XE6C4I.TT>G"K":O%DM%%%9&@4444 %%%% !1110 5C^*?^17U#_KD?YUL5
MC^*?^17U#_KD?YT >,U[/X8B2'PSIRH, PAC]3R?U->,5ZIX%U:.]T5;)F'V
MBU^4J3R4SP?Z?A4HIG544451)QGQ(B1M%M9B/G2XV ^Q4D_^@BO.;5BEW"ZG
M#+(I!_&NS^(>K1SW$&FPL&\@EY2.S'H/J!G\ZY;1;1K[6[*V49WS+G_=!R?T
M!J7N6MCV^N0^(W_(O6__ %]K_P"@/77UR'Q&_P"1>M_^OM?_ $!Z;)6YYM9H
M)+V!&Y5I%!'XU[Q7A-C_ ,A"V_ZZK_,5[M2B.05E>) #X:U$$9_T=C^E:M9?
MB/\ Y%O4?^O=_P"542>*U[5X<_Y%O3O^O=/Y5XK7M7AS_D6]._Z]T_E4Q*D4
M?'#E?"=T <;F0'_OH5Y'7L_BBS:^\-7T*#+>7O4=R5(;^E>,4,$>XZ/$D&BV
M,<>-JP( 1WX'-7:YKP5K$>HZ'%;LP^T6JB-U[E1]T_EQ^%=+5$A7&?$>)#HM
MK*1\ZW&T'V*L3_(5V=>:_$'6(KJ\ATZ!PRVY+2D'C>>,?@/YTGL-;G)V/_(0
MMO\ KJO\Q7NU>$V/_(0MO^NJ_P Q7NU*(Y%>^_Y!]S_UR;^1KPFO=K[_ )!]
MS_UR;^1KPFB01/4OA[;"'PZTV/FFF8Y]A@#^1_.NLKG_  2 /"-C@=?,S_WV
MU=!36PGN%%%%,1XSXI_Y&C4/^NI_E73?#,#.J''(\H?^AUS/BG_D:-0_ZZG^
M5=/\,_\ F*?]LO\ V>I6Y;V._HHHJB#Q#7 !X@U( 8 NI<#_ (&:[;X:JHLK
M]\?,9%!/L ?\:XK7?^1AU+_K[E_]#-=O\-O^0???]=5_E4K<M[';T4451!X1
M? #4+D 8 E; _$UZ1\.?^1>N/^OMO_0$KSB^_P"0A<_]=6_F:]'^'/\ R+UQ
M_P!?;?\ H"5*W+>QUDK%878=0I(KP3J<FO?2 1@C(->%ZA:M8ZC<6K@YAD9.
M?8T2%$])^'L2)X<9UP6DG8M^  Q_GUKK*\[^'FL1PR3:5,VTRMYD)/=L8(_(
M#\C7HE-;">X5E^(XDF\-ZBK]!;NP^H&1^H%:E<KXZUB.RT9[)7'VFZ&W:#R$
M[D_RIL2/*Z]F\+?\BOI__7(?SKQFO9O"W_(KZ?\ ]<A_.IB5(=XG=D\,ZB5.
M"86'X'@UXO7NFI6OVW2[NU'6:%D'U(XKPQE*L58$,#@@]J)!$]I\.1)#X;TY
M8Q@&W1C]2,G]2:U*Y3P)K$=[HZV+O_I%J,;3U9,\'\.GX"NKJD2PHHI RMG!
M!P<'!Z&@!:\E\=DGQ5< GHB ?]\BO6J\P^(=HT.NQ7./DGA'/^TO!_3;^=)[
M#CN<WI^IWFES--93F&1EVE@ <CKCGZ5H?\)?K_\ T$9/^^%_PIWA+^SWUQ+?
M4H8Y(9U*+OZ*_;\^GXUZ3_PBVA_] R#\C22*;/-/^$OU_P#Z",G_ 'PO^%-E
M\5ZY-$\4FH.R.I5@47D'KVKTW_A%M#_Z!D'Y&H[CP[X=M;>2>>PMHXHUW,S
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M[C_^@FM#XD?\AFT_Z]__ &8UG^!?^1KMO]Q__034]2^AZW7E7Q =F\3$$\+
M@'TY/]:]5KS?XCV;)J5I> '9)%Y9/NIS_)OTIO8E;E3X>Q))XD9G&6CMV9/K
ME1_(FO4Z\7\-ZJ-'URWNGSY.2DN/[IZ_EU_"O9HY$EC62-@R. RL#P0:$$AU
M%%(65<;B!DX&3WIB%K"\8N4\)WY4$DJHX]V -;M9VO6C7V@WUL@R[Q':/5AR
M/U% (\2KVOP[$D/AO3508!MT;\2,G]2:\4KU/P+K$=[HRV+N/M-J-NTGED[$
M?3I^'O4HIG5T4451)R7Q#B1_#L<AQN2X7:?J",?Y]*\NKN_B'K$<SPZ7"P8Q
M-YDV.S8P!^1/YBN$J'N6MCWZHY_^/>7_ '#_ "J2HY_^/>7_ '#_ "JR#P6O
M6_ O_(J6W^^__H1KR2O6_ O_ "*EM_OO_P"A&I13V.CKA_&/A&:^G;4M.7=,
MP_?0]"V/XA[^U=L[K'&TCG"J"Q/H!63_ ,)3H?\ T$X/S--B1XY+%)!(8YHW
MCD7JKJ01^%:%GXAU>PP+?4)U4=%9MR_D<BO7I+;3]7MHY)8(+J%URC,@;@^E
M8E]X"T:Z5C DEK(>AC8D9^A_IBE8=S$TGXB2B18M5A5HSP9HA@CW([_A7H$,
MT=Q"DT+J\;C<K*<@BO$=6TV;2-2FLIRK/&?O+T8$9!_*N\^'%[)-IUW9N25M
MW5DSV#9X_-2?QH3!H[6BBBJ)"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC7A->\W,9FM9HE(#.C*,].17FO\ PKG6/^?FQ_[[?_XFDQH[#P3_ ,BA8_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQAL8SM &?TJQ12L.X4444Q!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
8% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140550606043552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 08, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  08,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Arrowhead Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-0408024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">177 E. Colorado Blvd<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pasadena<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">304-3400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARWR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000879407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( )2 "%D'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "4@ A92X.=)NX    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)-
M:L,P$$:O4K2W1W9,*<+Q)J&K%@H-M'0GI$DB8OT@3;%S^\INXE#: Q2TT<RG
M-V] K0I"^8@OT0>,9##=C;9W2:BP9D>B( "2.J*5J<P)EYM['ZVD?(T'"%*=
MY &AYOP>+)+4DB1,P"(L1-:U6@D549*/%[Q6"SY\QGZ&:078HT5'":JR M9-
M$\-Y[%NX 2888;3INX!Z(<[5/[%S!]@E.2:SI(9A*(?5G,L[5/#^_/0ZKUL8
MET@ZA?E5,H+. =?L.OEMM=GN'EE7\[HI^$,^NYH+WHB&?TRN/_QNPM9KLS?_
MV/@JV+7PZU]T7U!+ P04    " "4@ A9F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M )2 "%FB"D"J800  "H1   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MG9AO<^(V$,:_BL:]Z;0S"?Z# R0%9@@A;>;N<AS09J:=OA"V $ULR95D"-^^
M*T-LVC-KVKR(+=O[^&?MZI%$?R?5J]XP9LA;F@@]<#;&9'>NJZ,-2ZENR8P)
MN+.2*J4&FFKMZDPQ&A=!:>(&GM=Q4\J%,^P7UZ9JV)>Y2;A@4T5TGJ94[>]9
M(G<#QW?>+\SX>F/L!7?8S^B:S9GY-9LJ:+FE2LQ3)C27@BBV&C@C_^X^N+$!
MQ1._<;;3)^?$?LI2RE?;>(H'CF>)6,(B8R4H'+9LS)+$*@''7T=1IWRG#3P]
M?U=_+#X>/F9)-1O+Y(7'9C-P>@Z)V8KFB9G)W2_L^$$%8"037?PGN\.S8>B0
M*-=&IL=@($BY.!SIV[$C3@/\,P'!,2 HN \O*B@?J*'#OI([HNS3H&9/BD\M
MH@&."YN5N5%PET.<&8[EEJF^:T#*7G"C8]C](2PX$S;*URWB]:Y(X 7A/\-=
M("@Q@A(C*/3:& ;Y8[341D&B_JPC.BB$]0JV>N]T1B,V<* \-5-;Y@R__\[O
M>#\A?.V2KXVI#Q]DE$,M&K+89ZP.#@_O77]$(,(2(KP,8LH4ES&9B)A TFMY
M<*4B?47^FA)X4[+=H(H38;C9DQE;<YM"@'RF:2T9KC-2\.(-V N9;BB,NHCE
MAD<TT5?D240MA+13DG8N(04UJ3*IJ#6'*S(WT)%$*C*6N3!J#\>X%A\7?Y@@
MA-V2L'L)X2-/&'G.TV7] ,4U/,^_;O>\,$!X>B5/[Q*>!7TC3S'4'U]!1@I/
M/4^'*X:=:R_T>GCIW99XMY?@C>(8QCW4R?&$?(+GR!=1FT5<T>]VR:0%)9!
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "4@ A9JL0B%C,!   B @  #P
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M2P$"% ,4    " "4@ A92X.=)NX    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "4@ A9F5R<(Q &  "<)P
M$P              @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( )2 "%FB"D"J800  "H1   8              " @0T(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "4@ A9GZ ;\+$"  #B#
M#0              @ &D#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( )2
M"%F7BKL<P    !,"   +              "  8 /  !?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( )2 "%FJQ"(6,P$  "("   /              "  6D0  !X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "4@ A9)!Z;HJT   #X 0  &@
M            @ ')$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " "4@ A999!YDAD!  #/ P  $P              @ &N$@  6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #X$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="arwr-20240808.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="arwr-20240808.htm">arwr-20240808.htm</File>
    <File>arwr-20240808.xsd</File>
    <File>arwr-20240808_lab.xml</File>
    <File>arwr-20240808_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "arwr-20240808.htm": {
   "nsprefix": "arwr",
   "nsuri": "http://www.arrowheadresearch.com/20240808",
   "dts": {
    "inline": {
     "local": [
      "arwr-20240808.htm"
     ]
    },
    "schema": {
     "local": [
      "arwr-20240808.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "arwr-20240808_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "arwr-20240808_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 25
   },
   "report": {
    "R1": {
     "role": "http://www.arrowheadresearch.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240808.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240808.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-24-036113-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-24-036113-xbrl.zip
M4$L#!!0    ( )2 "%D8I/\_O \  $AU   1    87)W<BTR,#(T,#@P."YH
M=&WM'6MSVDCR^_Z*.?9N8U<AH1=/VURQF"1<$ML%I+)U7ZX&:3"S%I)V)!G8
M7W_=(XF' 1L<$G#B? F2YM'O[NGI&9__>S)RR3T3(?>]BS>ZJKTAS+-]AWNW
M%V\:W6:[_>;?]5_._Z$H?_S>^4@N?3L>,2\B3<%HQ!PRYM&01$-&OOCBCM]3
M<N/2:."+D:(DW9I^,!7\=A@10S.LK%GV5=0&95W7^Y6*TA]8NF(Q8Z!0T]24
M?M72RUIE8!8-+7];JU9,QRB:IJ*9U8IBE0SHP(I]I5C2:;%8J@Y,Q\D[-7N@
MLS(S#,?02Y;6K]*B9E"C9)9M:FO4-N6\PPAP!KR]\"(WC**@5BB,QV-U;*J^
MN"WHU6JU,,$VN:11C4^6VDWZPI4M#4TW"]QSN<>0.%ES_,XW]="P1QA1SV:S
M]B%?!P>TU0M_?/K8M8=L1)6'O?@D4D)F+_6$9_76OU^ J1 )ZH7(#QH!AQ'D
MHJ)5%%//QH&6=X\ BY_[-%R<=GWKQ^8T-$4S%-V88;PRZ1+M\6O6U&%SXLBY
M,ASA XYLRH8UEX*\YIBG?.[FZN=#1IWZ^8A%E&!7A?T5\_N+7-/W(I!=I3<-
M !\[>;K(16P2%22_"_5??OGE/.*1R^I4C(6"(JM5M,IY(7EY7DB&[OO.M'[N
M\'L21E.77>0<'@8NG=8\WV,  )_4L"$3R4_N.,R3/^'[%2B0X'8R_R3JL,%%
MSE: 'QX=X4B,UUH>3#=M G2"NFW/89,/;)HCW+G(#13#R-4U^%<I5RVM?%Y8
M&G6'21J@QP[J\EN7WN9(PJ^+'#"X-N 3YB@#ZB+?TUG-7/UMXV.WM3)A81E#
MP09,@ EAX1K&(&=KH11H (E(3M<B8,=%+N2CP$4QD^^& B%>XH$Z"1W@D)QO
M/DDZ9^C'0CY)Y:NE:$O8$>WL/9.$S9ZX@\\#S@21,+&URM1L?U@F^,/.]>S5
M\N@!D,=WLB=07A%=@LFL(SZH@BA5#[_-P'0V-,V^9,_9)(4EO#,BS:A26!#(
M HAM(KM('?Z4Q?P?4F_>)Y7W$?>4(4.S7K.*070VYDXTK.F:]J^<;%<_#P,*
M M$7R+'D=S+(RE (L$)=?NO5;* @$S!"1/LNRQKT?0& *[;ONC0(62W[<98I
M76)Z%-GI;$3%+0#7]Z/(']40-O!N$;>IFTXBYTL^S\%6M03T" @4.=G,Z6<5
M/A56WU<K:E5;_TE3=?F^(,<3V<>,8D&4DWT $R3-10ZLV#*RD1_ (&4 GX2^
MRQWRJR;_G0740=]<TX@.HV13%"3N6Q(7I\R^ P2^J&6##T!\0.U'W)W6WO3X
M"'3XBHU)QQ]1[TT^!*L.+D?P0=(PY'^SFHX4EH_C!+DRC"/9D2*KZT4@[.>K
M=J]U2;J]1J_5)<L2<83@=EO-SYUVKPVP-JXN2>N/YOO&U;L6:5Y_^M3N=MO7
M5X?$P=@*AR^-[OOVU;O>]56>7*I-%>*OHE7=#/>RXH!TG1U>,PU#K90KQZ28
M*?3[T,V4'JCJY@9J'T+VWUYW/I'MPXAL19 $54FP "ZCHGQ8C11>)>_H)$\:
MDV,Q66!T.ZVK'NFT;JX[O>,WL3>?.]W/#0"X=TW 9?30+^@FN>X0O7AR>4JN
MWQX]"KWW+;+@[6:>KM'L ?A$KYK6,?'!6HO$[M;J1L;-K22:7E[\./!&&<$0
M0^RF.'2J3!D5"O-F:Z%<O1'?QF%$*GF9U=C:TAT+P68L/83((<F)/R =%O@B
M.J1T:5O!>Y(!#%+@<@9L9_>8 A,2?N:<OCJV8W%LQQ)#[9KJZ;!;'F+:++J"
M+YF=,<'.".&/<>5.;H84;)3-8LG>,$_:GJT>D>%YJ$OK#<]):T+M2.*/&B5F
M>!,:DC!@-F94',(]PJ.0V( SP'KZNF@YN(8=1EQV<P[?E\W5JEJJEG9ELZFK
M9:/T*)NW?U\L5G?J\>* ,K=2B$W2GXFV$4S(6M/PD,D)?P]@&JUG^ RP_[Z
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M2=M7(4VIVP[#F(EGB&KY552?(:HF4RQR8F\GJ]@8VIZNBNKA4J76L6=*OP6
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M2T=K=]O<T)?2CV<[XC[BCN.R?>->VJI69N?-K"?8_C11EL\$[/D@]R'*C3
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MM%ZE#<:QB\.6>=,UZY\?K:(U]/N]7?P&4$L#!!0    ( )2 "%G;"O*'QBD
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MD9AJ4!W64F9G#=G+O88>::^AV;6LM"^R]-E25'C9_^T;02$>Y\1]7\]^>2G
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MDP^5>@^H!@SU04[5O"'%QQ&M))-IIH([DZGF+II/ /=3*%.PFCR%@1LH0RH
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MAA 0?AM/;U07@@TR-O 38*_ O4VA17"+3 V\#)W# VE(YD*AKP)DO];)PN.
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M_&_+BX]^&BAW C_&B>^]_U]02P,$%     @ E( (6>P<N&A""@  %%@  !4
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MM/+AQKP[6:3SFYE9OW==F*0][*PH&E&K+'F5942J+/_:)389D/Z!\BVW<SU
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M 910!3 ,$\"5T"#2D&L8&2-EX@9AA](X*%KQH*GN.;-U]5=?* _0"UYHNG>
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MI =N[4X&D/8LX,B0M=O9YJNC71=:FSUN8?SQ_M7ZG73Y);+O7_T/4$L#!!0
M   ( )2 "%ED;I%[W@8   HS   5    87)W<BTR,#(T,#@P.%]P<F4N>&UL
MU5MM4^0V$O[.KYB;^WIB]&9+HA92'-F]HHYDJ5U22>6+2R^M&5<\-J4Q"_S[
M:QLF@042!\\5WB_,V-/6TWKZL=3=-N^^NUE7LR^0-F53'\[9/IW/H/9-*.OE
MX?RGBP]$S[\[VMM[]P]"?OGWI[/9]XV_6D/=SDX2V!;"[+IL5[-V!;.?F_1;
M^<7.SBO;QB:M"3GJ+SMI+F]3N5RU,TZYW)IM?TT'43'&G-;$1<F(!!Z)%8(2
M9R135$>1<?JOY8'1(O!,"$*%T43F'"^ S)$L9S;+<A-%"/V@55G_=M#]<78#
M,YQ>O>D/#^>KMKT\6"RNKZ_W;URJ]INT7'!*Q6)K/;\WOWEB?RUZ:V:,6?2_
M_FZZ*9\SQ&'9XI<?SC[[%:PM*>M-:VO? 6S*@TU_\JSQMNU9_TN_9B]:=$=D
M:T:Z4X1Q(MC^S2;,C_9FLSLZ4E/!)XBS[O.G3Z>/(&U*S?4*;$BP 9O\:M\W
MZT5GN3AI4!GH<S]&>WL)A_--N;ZL8'MNE2 >SFVZ3J0++M54=\C_O+MP\8<#
ME]W@==M/^ Q/W%_?H8QP!FY:J /<S70+537^D5'5\=S\?F5E'53]V2) 6?2C
M'KM-FZQO"QJ#X<(I(A1S1+)(B6$Q(UF03%(0S&7B\=P[WS?H?!^6#?C]9?-E
M@0-C>+CHOG3$B)Z4)W!W!+W.[^U]>(&V!14^-]0XPL"CVT8%8@%O%6<,RR'F
MF>$PRNV':(^]?AC8X^1G30J0<"'9PF$,GP3YL83O+1:7-N% Q*_**FROCJE9
M[R)6;;,#YN["@N[.9SCK""E!.+N+RHN3ZV?6XO(*O>4N(GX.J6S"^SI\C^MO
MX7.6,YI+HK031,8@D 63$0W,!FL]DW:<8I^%':0!/GT-O)[+-Q;#^[HMV]M/
ML"P[)NKV1[N&@G,1K.?HL #<29T"W"+!$RV9SKB,1F=^E!:>0QTD!3%=*8QF
M<A)*.,6<+5TVJ2?^,_(/)\U5W:;;DR9 H0""\"8GZ+<ADII.V%E.,AMI-);R
MP/0.A/&G3@S2B9RZ3G;'\R1D\Z&LX,>KM8-4Y+EE/AA)?([)MZ19),8)1P(+
MF3"1ZTSL8O'X W&0(+*I"^*5#$XB^A?VYC0@5V4L[TJ1^XDPQ2":3)"0*45D
MAK69U08%S93142MAF=F!%%Z 'Z2+?.JZV 6WDQ#)<>AJL<W]!]9NP(I@#>/>
M>^(#PT0I@T",B9IX;Y0),@@>\AT(Y!GH0>)04Q?'6$XG*@Q>F)QC(85Y<V#6
M$IEC364<C81YZZS.04B(_Q=A\$'"T-^>,/X>IU,2Q@E^_9@NFNNZ4'FNG(@2
M\R*#4]!@NL2:8YUEC<Y%"$SN(K=X CQ(%.8;$<4K^9R2)/J$^6,Z3\V7LO90
M2!% "BRXH\F[[@M88G%?Q$,A'0O2*#&N>?%GZ,/Z6/0;4<<8:J<DD?-FT]KJ
MU_*R+Z@<SQCS(A!ENCI<T1Q+<"S&L\#S8*VQ+HYK;+Z,/4P>$^YS[HC6-Q9'
MM^H=)[!W]343-$:!>;.A@'[C?JBU541C;F0MU7G4890<'J(-$\"$FYROINZ-
M0]X]&*O.5TV]+:Q]IJT,RG>5$OK.&6Y\W:&QTN9*4ZGIN'+C:\1AH9]P4W,4
MA6\<_I]3V;90GS3K]55]7SQOBLBB<3@)XJRD1$J'=7/@FBCEI=9:A3S(41IX
M%G:8$";<M1Q/YANKX7-3E;YLRWKY R8XJ;15 3HX+4-.P&4YD4@,T59H$HQ@
M8$#PJ,95$T\QA^E@PLW*D32^L0C.$W0*!DQL^R>WW4/_]#&B'P4%F0?%(_%&
M9KBO,48,51*+(AUY]T:"&-EQ>!E[F"@FW*G<$:W3$L?I9G,%Z>%<N(LQ2&%(
M$%:@T'W N4A/7*  -FB>A7%/O_[*@V%"F7#7<J<4O_6& OX*-\5;QMU%V590
M!,JBSK%(%CI#J><99D4JLX3EH#C$S!HQ+KO\&G&8'";<JQQ%X1N'_R+9[MW&
MS[=KUU2%Y9(;%2/1S$1<W+ &M@S7.N4MCU@Q63KRH><CN&&!GW _\O7D3>2F
M?W_C5[9>0O^21\:IB%9P$A18(H6B1#NLD#-'*1BLE6E4.[GQ'Z(.>W-JPEW'
MT51.HMOX?@UIB5+^3VJNVQ5N;I>VOBVH]0Z\$02$#E@7=5E/S"(!3'F" 4I=
MV,7CJV?!APEC\OW&\<1.0A\G2%FRU2FF.#?_A=M"<Q\<5YRPF.-:QRSF-CDU
MA/L<@@S<";^+-ZB^@AVFB0FW(,>3^<9J.,9\-W0Y[X?*+@LGK>$^<\1+Y$)J
M9X@UDA-OH\*MSSGMQJ4+C^"&17_"7<C7D[>SJ+];/"'O#$\<[=W_T/WI_G7B
M:.]_4$L! A0#%     @ E( (61BD_S^\#P  2'4  !$              ( !
M     &%R=W(M,C R-# X,#@N:'1M4$L! A0#%     @ E( (63[V/9=S @
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H<BTR,#(T,#@P.%]P<F4N>&UL4$L%!@     %  4 2@$   ].      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>arwr-20240808_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="arwr-20240808.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2024-08-08</startDate>
            <endDate>2024-08-08</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0000879407</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-08-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Arrowhead Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38042</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">46-0408024</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">177 E. Colorado Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 700</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Pasadena</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">91105</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">304-3400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">ARWR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-24">2024-08-08</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-25">2024-08-08</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
